TREACE MEDICAL CONCEPTS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
TMCI$4.78+18.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $12,982 | $19,473 |
| Marketable securities, short-term | 110,216 | 61,779 |
| Accounts receivable, net of allowance for doubtful accounts of $980 and $735 as of December 31, 2023 and December 31, 2022, respectively | 38,063 | 29,196 |
| Inventories | 29,245 | 19,330 |
| Prepaid expenses and other current assets | 7,853 | 3,624 |
| Total current assets | 198,359 | 133,402 |
| Property and equipment, net | 22,298 | 15,338 |
| Intangible assets, net of accumulated amortization of $475 and $0 as of December 31, 2023 and December 31, 2022, respectively | 9,025 | — |
| Goodwill | 12,815 | — |
| Operating lease right-of-use assets | 9,264 | 10,138 |
| Other non-current assets | 146 | 146 |
| Total assets | $251,907 | $159,024 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $11,835 | $8,668 |
| Accrued liabilities | 10,458 | 6,216 |
| Accrued commissions | 10,759 | 7,356 |
| Accrued compensation | 7,549 | 7,666 |
| Other liabilities | 4,432 | 339 |
| Total current liabilities | 45,033 | 30,245 |
| Long-term debt, net of discount of $992 and $1,289 as of December 31, 2023 and December 31, 2022, respectively | 53,008 | 52,711 |
| Operating lease liabilities, net of current portion | 15,891 | 15,539 |
| Other long-term liabilities | 37 | — |
| Total liabilities | 113,969 | 98,495 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Common stock, $0.001 par value, 300,000,000 shares authorized; 61,749,654 issued and outstanding as of December 31, 2023; 300,000,000 shares authorized; 55,628,208 issued and outstanding as of December 31, 2022 | 62 | 55 |
| Additional paid-in capital | 271,973 | 145,221 |
| Accumulated deficit | (134,247) | (84,720) |
| Accumulated other comprehensive (loss) income | 163 | (27) |
| Treasury stock, at cost; 1,218 and 0 shares as of December 31, 2023 and December 31, 2022 | (13) | — |
| Total stockholders’ equity | 137,938 | 60,529 |
| Total liabilities and stockholders’ equity | $251,907 | $159,024 |
PTREACE MEDICAL CONCEPTS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.